Related Experiment Video

Updated: May 19, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Cytotoxicity, anti-angiogenic, apoptotic effects and transcript profiling of a naturally occurring naphthyl butenone,

Victor Kuete1, Tolga Eichhorn, Benjamin Wiench

  • 1Department of Biochemistry, Faculty of science, University of Dschang, Dschang, Cameroon. kuetevictor@yahoo.fr.

Cell Division
|August 16, 2012
PubMed
Abstract

Insights

Guieranone A (GA), a natural compound from Guiera senegalensis, shows significant anticancer activity against various cell lines. This compound also exhibits anti-angiogenic properties and induces apoptosis, suggesting its potential in cancer chemotherapy.

Area of Science:

  • Natural Product Chemistry
  • Pharmacology
  • Cancer Research

Background:

  • Malignant diseases cause approximately 13% of global deaths annually.
  • Natural products are a vital resource for novel anticancer drug development.
  • This study investigates guieranone A (GA), a naphtyl butanone from Guiera senegalensis leaves.

Purpose of the Study:

  • To evaluate the cytotoxic potential of guieranone A (GA).
  • To assess the anti-angiogenic activity of GA.
  • To explore the molecular mechanisms underlying GA's effects.

Main Methods:

  • Cytotoxicity assays on 12 cancer cell lines and a normal cell line.
  • In vitro anti-angiogenesis assay using quail embryo chorioallantoic membrane.
  • Apoptosis and cell cycle analysis.
  • Ingenuity Pathway Analysis (IPA) for gene expression profiling.

Main Results:

  • GA demonstrated activity against 91.67% of tested cancer cell lines, with IC50 < 4 μg/ml in 83.33%.
  • GA showed potent cytotoxicity against human lymphoblastic leukemia and lung adenocarcinoma cell lines, comparable to doxorubicin.
  • Low cytotoxicity was observed in normal hepatocytes (AML12).
  • GA exhibited significant anti-angiogenic activity (51.9% inhibition) and induced apoptosis and cell cycle arrest.
  • IPA identified Cell Cycle: G2/M DNA Damage Checkpoint Regulation and ATM Signaling as key pathways affected by GA.

Conclusions:

  • Guieranone A (GA) possesses significant cytotoxic potential against a broad spectrum of cancer cell lines.
  • GA demonstrates promising anti-angiogenic activity and induces cancer cell death pathways.
  • These findings support the potential utility of GA in cancer chemotherapy.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...